Results

1–10 of 153 results for Retinal Vascular Disease

Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Subclinical Retinal Ischemia in Individuals With Atrial Fibrillation
Mathieu F Bakhoum, MD, PhD
Annual Meeting Talks
2022
Spatial Correlation Between Retinal Ischemia and Reactive Choroidal Changes in Retinal Vein Occlusion
Junyeop Lee, MD, PhD
Annual Meeting Talks
2022
Impact of COVID-19 and Delay on Macular Edema After Retinal Vein Occlusion (MEfRVO) Comparing Ozurdex vs Anti-VEGF Therapy
John J. Huang, MD
Annual Meeting Talks
2022
Point of Care Diagnosis of CRAO With OCT at the Stroke Center: Lessons Learned in Our First Year
Gareth Lema, MD, PhD
Annual Meeting Talks
2022
Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection and Baseline BCVA on Outcomes in CRVO: Post Hoc Analysis of the COPERNICUS and GALILEO Trials
Dilsher S. Dhoot, MD
Annual Meeting Talks
2022
Longitudinal Macular Thickness and Microvascular Changes in Children with Sickle Cell Disease
Adrienne W. Scott, MD, FASRS
Annual Meeting Talks
2022
Venous Loop
Sidney A Schechet, MD
Retina Image Bank: Images of the Week
2024
Anti-VEGF Therapy to Prevent Macular Fibrosis in Coats Disease
On Demand Cases, Courses, and Papers
2022